{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:24:00Z","timestamp":1776097440619,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Central venous catheters (CVCs) are essential for drug delivery in pediatric oncology patients but are associated with complications such as infection and thrombosis. This study aimed to compare the effects of taurolidine\u2013citrate and unfractionated heparin lock solutions on catheter function, infection and thrombosis rates, and inflammatory markers in children with malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomized, controlled trial, 76 pediatric oncology patients were allocated to receive either TauroLock\n                      <jats:sup>\u2122<\/jats:sup>\n                      -HEP500 (containing taurolidine, 4% citrate, and 500\u00a0IU\/mL heparin) or standard unfractionated heparin as the catheter lock solution. Patients were followed for 6\u00a0months. Laboratory evaluations, including complete blood count (CBC), high-sensitivity\n                      <jats:italic>C<\/jats:italic>\n                      -reactive protein (hs-CRP), and interleukin-6 (IL-6), were performed at baseline, 1\u00a0month, and 6\u00a0months, or upon clinical suspicion of infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 6\u00a0months, hs-CRP levels were significantly lower in the taurolidine\u2013citrate group (2.1\u2009\u00b1\u20090.2 vs. 5.5\u2009\u00b1\u20092.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), as was total WBC count (3792.1\u2009\u00b1\u2009325.3 vs. 4994.5\u2009\u00b1\u2009462.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028). IL-6 levels showed no statistically significant difference (9.2\u2009\u00b1\u20091.9 vs. 14.0\u2009\u00b1\u20093.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.067). The incidence of catheter-related infections (HR 3.55, 95% CI 0.68\u201318.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.460) and thrombosis (HR 4.13, 95% CI 0.43\u201339.91,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.221) did not differ significantly between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taurolidine\u2013citrate exhibited a modest anti-inflammatory effect, reflected by reduced hs-CRP and WBC levels, without significant improvement in catheter-related complications or IL-6. The lack of major clinical benefit may relate to the heterogeneous and immunocompromised nature of pediatric oncology patients. Larger, adequately powered studies are warranted to clarify the long-term efficacy and safety of taurolidine\u2013citrate in this population. Clinical Trials as IRCT20201107049296N4.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40001-025-03413-6","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:52:07Z","timestamp":1763466727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of TauroLock\u2122-HEP500 versus unfractionated heparin for prevention of catheter complications in children with malignancy: a prospective, randomized, controlled study"],"prefix":"10.1186","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-0094","authenticated-orcid":false,"given":"Aziz","family":"Eghbali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4878-3721","authenticated-orcid":false,"given":"Arya","family":"Shirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-0041","authenticated-orcid":false,"given":"Mobin","family":"Obeidinia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9727-4459","authenticated-orcid":false,"given":"Makan","family":"Ziafati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-7656","authenticated-orcid":false,"given":"Ali","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-3123","authenticated-orcid":false,"given":"Kazem","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"8","key":"3413_CR1","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/pbc.24482","volume":"60","author":"MM Handrup","year":"2013","unstructured":"Handrup MM, M\u00f8ller JK, Schr\u00f8der H. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin. Pediatr Blood Cancer. 2013;60(8):1292\u20138.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3413_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12885-025-13751-7","volume":"25","author":"A Eghbali","year":"2025","unstructured":"Eghbali A, Adibifar M, Ghasemi A, Afzal RR, Moradi K, Eghbali A, et al. The effect of oral curcumin on vincristine-induced neuropathy in pediatric acute lymphoblastic leukemia: a double-blind randomized controlled clinical trial. BMC Cancer. 2025;25(1):344.","journal-title":"BMC Cancer"},{"key":"3413_CR3","doi-asserted-by":"publisher","first-page":"1507996","DOI":"10.3389\/fphar.2024.1507996","volume":"15","author":"A Eghbali","year":"2025","unstructured":"Eghbali A, Eghbali A, Ashayeri N, Fadayi F, Ghaffari K, Ghasemi A. Effects of oral l-carnitine supplementation on liver enzymes in pediatric acute lymphoblastic leukemia patients in the maintenance phase of treatment: a randomized clinical trial study. Front Pharmacol. 2025;15:1507996.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3413_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.htct.2022.02.004","volume":"45","author":"A Eghbali","year":"2023","unstructured":"Eghbali A, Kohpar FK, Ghaffari K, Afzal RR, Eghbali A, Ghasemi A. Evaluating aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: a triple-blinded randomized clinical trial. Hematol Transfus Cell Ther. 2023;45(3):281\u20139.","journal-title":"Hematol Transfus Cell Ther"},{"key":"3413_CR5","doi-asserted-by":"publisher","first-page":"1284326","DOI":"10.3389\/fphar.2023.1284326","volume":"14","author":"A Eghbali","year":"2023","unstructured":"Eghbali A, Nourigheimasi S, Ghasemi A, Afzal RR, Ashayeri N, Eghbali A, et al. The effects of curcumin on hepatic T2* MRI and liver enzymes in patients with \u03b2-thalassemia major: a double-blind randomized controlled clinical trial. Front Pharmacol. 2023;14:1284326.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3413_CR6","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_356_22","volume":"12","author":"A Eghbali","year":"2023","unstructured":"Eghbali A, Bagherloo T, Ghasemi A, Afzal RR, Eghbali A, Ghaffari K. The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy. Adv Biomed Res. 2023;12(1):158.","journal-title":"Adv Biomed Res"},{"key":"3413_CR7","doi-asserted-by":"publisher","first-page":"1295816","DOI":"10.3389\/fphar.2024.1295816","volume":"15","author":"A Eghbali","year":"2024","unstructured":"Eghbali A, Sadeghian M, Ghasemi A, Afzal RR, Eghbali A, Ghaffari K. Effect of oral silymarin on liver function in pediatric acute lymphoblastic leukemia in the maintenance phase: a double-blind randomized clinical trial. Front Pharmacol. 2024;15:1295816.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3413_CR8","first-page":"147","volume":"10","author":"NA Ghandforoush","year":"2016","unstructured":"Ghandforoush NA, Chahardouli B, Rostami S, Ghadimi H, Ghasemi A, Alimoghaddam K, et al. Evaluation of minimal residual disease in acute myeloid leukemia with NPM1 marker. Int J Hematol Oncol Stem Cell Res. 2016;10(3):147.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"5","key":"3413_CR9","first-page":"213","volume":"7","author":"A Ghasemi","year":"2015","unstructured":"Ghasemi A, Ghotaslou A, Ghaffari K, Mohammadi M. Methylation status of SOX17 and RUNX3 genes in acute leukemia. Iran J Blood Cancer. 2015;7(5):213\u20139.","journal-title":"Iran J Blood Cancer"},{"issue":"4","key":"3413_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10989-021-10260-6","volume":"27","author":"A Ghasemi","year":"2021","unstructured":"Ghasemi A, Ghavimi R, Momenzadeh N, Hajian S, Mohammadi M. Characterization of antitumor activity of a synthetic moronecidin-like peptide computationally predicted from the tiger tail seahorse hippocampus comes in tumor-bearing mice. Int J Pept Res Ther. 2021;27(4):2391\u2013401.","journal-title":"Int J Pept Res Ther"},{"key":"3413_CR11","doi-asserted-by":"publisher","first-page":"1263834","DOI":"10.3389\/fphar.2023.1263834","volume":"14","author":"K Ghaffari","year":"2023","unstructured":"Ghaffari K, Moradi-Hasanabad A, Sobhani-Nasab A, Javaheri J, Ghasemi A. Application of cell-derived exosomes in the hematological malignancies therapy. Front Pharmacol. 2023;14:1263834.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3413_CR12","first-page":"760","volume":"14","author":"M Jafari","year":"2023","unstructured":"Jafari M, Ansari Damavandi S, Charmduzi F. Transformation of acute lymphoblastic leukemia with a precursor B-cell immunophenotype to burkitt\u2019s lymphoma: a case report. Caspian J Intern Med. 2023;14(4):760\u20134.","journal-title":"Caspian J Intern Med"},{"issue":"1","key":"3413_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jmv.25423","volume":"92","author":"A Ghasemi","year":"2020","unstructured":"Ghasemi A, Zadsar M, Shaiegan M, Samiei S, Namvar A, Rasouli M, et al. Human platelet antigens polymorphisms; association to the development of liver fibrosis in patients with chronic hepatitis C. J Med Virol. 2020;92(1):45\u201352.","journal-title":"J Med Virol"},{"issue":"1","key":"3413_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/11297298211026453","volume":"24","author":"F Brescia","year":"2023","unstructured":"Brescia F, Pittiruti M, Scoppettuolo G, Zanier C, Nadalini E, Bottos P, et al. Taurolidine lock in the treatment of colonization and infection of totally implanted venous access devices in cancer patients. J Vasc Access. 2023;24(1):87\u201391.","journal-title":"J Vasc Access"},{"issue":"12","key":"3413_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMra2213296","volume":"389","author":"NP O\u2019Grady","year":"2023","unstructured":"O\u2019Grady NP. Prevention of central line-associated bloodstream infections. N Engl J Med. 2023;389(12):1121\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"3413_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/annonc\/mdi111","volume":"16","author":"G Fratino","year":"2005","unstructured":"Fratino G, Molinari A, Parodi S, Longo S, Saracco P, Castagnola E, et al. Central venous catheter-related complications in children with oncological\/hematological diseases: an observational study of 418 devices. Ann Oncol. 2005;16(4):648\u201354.","journal-title":"Ann Oncol"},{"issue":"2","key":"3413_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/2229-5151.134184","volume":"4","author":"R Gahlot","year":"2014","unstructured":"Gahlot R, Nigam C, Kumar V, Yadav G, Anupurba S. Catheter-related bloodstream infections. Int J Crit Illn Inj Sci. 2014;4(2):162\u20137.","journal-title":"Int J Crit Illn Inj Sci"},{"issue":"8","key":"3413_CR18","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1128\/IAI.73.8.4596-4606.2005","volume":"73","author":"RM Shanks","year":"2005","unstructured":"Shanks RM, Donegan NP, Graber ML, Buckingham SE, Zegans ME, Cheung AL, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun. 2005;73(8):4596\u2013606.","journal-title":"Infect Immun"},{"key":"3413_CR19","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063264","author":"M Takashima","year":"2024","unstructured":"Takashima M, Ezure Y, Furuya-Kanamori L, Wolf J, Dufficy M, Gibson V, et al. Pediatric central venous access device lock solutions: a network meta-analysis. Pediatrics. 2024. https:\/\/doi.org\/10.1542\/peds.2023-063264.","journal-title":"Pediatrics"},{"key":"3413_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jhin.2023.11.003","volume":"143","author":"I Savarese","year":"2024","unstructured":"Savarese I, Yazami S, De Rose DU, Carkeek K, Campi F, Auriti C, et al. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study. J Hosp Infect. 2024;143:76\u201381.","journal-title":"J Hosp Infect"},{"issue":"1","key":"3413_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/11297298211023295","volume":"24","author":"H Ezzat","year":"2023","unstructured":"Ezzat H, Elsharkawy M, Rezk K, Mohsen R, Mansour A, Emara A. Effect of taurolidine citrate and unfractionated heparin on inflammatory state and dialysis adequacy in hemodialysis patients. J Vasc Access. 2023;24(1):45\u201351.","journal-title":"J Vasc Access"},{"issue":"9","key":"3413_CR22","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1093\/cid\/cir257","volume":"52","author":"NP O\u2019Grady","year":"2011","unstructured":"O\u2019Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162\u201393.","journal-title":"Clin Infect Dis"},{"issue":"1S","key":"3413_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/NAN.0000000000000396","volume":"44","author":"LA Gorski","year":"2021","unstructured":"Gorski LA, Hadaway L, Hagle ME, Broadhurst D, Clare S, Kleidon T, et al. Infusion therapy standards of practice. J Infus Nurs. 2021;44(1S):S1\u2013224.","journal-title":"J Infus Nurs"},{"issue":"10","key":"3413_CR24","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.6004\/jnccn.2018.0078","volume":"16","author":"CS Denlinger","year":"2018","unstructured":"Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, et al. Survivorship, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(10):1216\u201347.","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"3413_CR25","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063\u201371.","journal-title":"J Clin Oncol"},{"key":"3413_CR26","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s11255-012-0339-1","volume":"45","author":"T Silva","year":"2013","unstructured":"Silva T, Mendes M, Abr\u00e3o JMG, Caramori J, Ponce D. Successful prevention of tunneled central catheter infection by antibiotic lock therapy using cefazolin and gentamicin. Int Urol Nephrol. 2013;45:1405\u201313.","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"3413_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/ki.2009.303","volume":"76","author":"SL Goldstein","year":"2009","unstructured":"Goldstein SL, Ikizler TA, Zappitelli M, Silverstein DM, Ayus JC. Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int. 2009;76(10):1063\u20139.","journal-title":"Kidney Int"},{"issue":"5","key":"3413_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ki.2011.178","volume":"80","author":"S Swaminathan","year":"2011","unstructured":"Swaminathan S, Shah SV. Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease. Kidney Int. 2011;80(5):453\u201363.","journal-title":"Kidney Int"},{"issue":"2","key":"3413_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1152\/physrev.00024.2005","volume":"86","author":"A Tedgui","year":"2006","unstructured":"Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515\u201381.","journal-title":"Physiol Rev"},{"key":"3413_CR30","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.65807","author":"TS Akp\u0131nar","year":"2013","unstructured":"Akp\u0131nar TS, Han\u00e7er VS, Nal\u00e7ac\u0131 M, Diz-K\u00fc\u00e7\u00fckkaya R. MPL W515L\/K mutations in chronic myeloproliferative neoplasms. Turk J Hematol. 2013. https:\/\/doi.org\/10.4274\/tjh.65807.","journal-title":"Turk J Hematol"},{"key":"3413_CR31","doi-asserted-by":"crossref","unstructured":"van den Bosch CH, Loeffen Y, van der Steeg AF, van der Bruggen J-TT, Frakking FN, Fiocco M, et al. CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients. BMJ open. 2023;13(3):e069760.","DOI":"10.1136\/bmjopen-2022-069760"},{"key":"3413_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jhin.2021.10.022","volume":"123","author":"C Van Den Bosch","year":"2022","unstructured":"Van Den Bosch C, Jeremiasse B, Van Der Bruggen J, Frakking F, Loeffen Y, Van De Ven C, et al. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis. J Hosp Infect. 2022;123:143\u201355.","journal-title":"J Hosp Infect"},{"issue":"4","key":"3413_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jhin.2012.01.003","volume":"80","author":"M D\u00fcmichen","year":"2012","unstructured":"D\u00fcmichen M, Seeger K, Lode H, K\u00fchl J, Ebell W, Degenhardt P, et al. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. J Hosp Infect. 2012;80(4):304\u20139.","journal-title":"J Hosp Infect"},{"issue":"2","key":"3413_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/0189-6725.132806","volume":"11","author":"E Ince","year":"2014","unstructured":"Ince E, O\u011fuzkurt P, Temiz A, Ezer SS, Gezer H\u00d6, Yazici N, et al. Complications of total implantable access ports and efficacy of Taurolidine-citrate lock solution against catheter-related infections. Afr J Paediatr Surg. 2014;11(2):138\u201342.","journal-title":"Afr J Paediatr Surg"},{"key":"3413_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-8-102","volume":"8","author":"A Simon","year":"2008","unstructured":"Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008;8:1\u20138.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"3413_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jpc.14506","volume":"56","author":"CY Chong","year":"2020","unstructured":"Chong CY, Ong RYL, Seah VXF, Tan NWH, Chan MY, Soh SY, et al. Taurolidine\u2013citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology\u2013oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates. J Paediatr Child Health. 2020;56(1):123\u20139.","journal-title":"J Paediatr Child Health"},{"issue":"2","key":"3413_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01521-19","volume":"64","author":"C Gudiol","year":"2020","unstructured":"Gudiol C, Arnan M, Aguilar-Guisado M, Royo-Cebrecos C, S\u00e1nchez-Ortega I, Montero I, et al. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients. Antimicrob Agents Chemother. 2020;64(2):10\u20131128.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3413_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000470911","volume":"93","author":"R Longo","year":"2017","unstructured":"Longo R, Llorens M, Goetz C, Platini C, Eid N, Sellies J, et al. Taurolidine\/citrate lock therapy for primary prevention of catheter-related infections in cancer patients: results of a prospective, randomized, phase IV trial (ATAPAC). Oncology. 2017;93(2):99\u2013105.","journal-title":"Oncology"},{"issue":"11","key":"3413_CR39","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.2215\/CJN.0000000000000278","volume":"18","author":"AK Agarwal","year":"2023","unstructured":"Agarwal AK, Roy-Chaudhury P, Mounts P, Hurlburt E, Pfaffle A, Poggio EC. Taurolidine\/Heparin lock solution and catheter-related bloodstream infection in hemodialysis: a randomized, double-blind, active-control, phase 3 study. Clin J Am Soc Nephrol. 2023;18(11):1446\u201355.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"3413_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111216","volume":"9","author":"ED Olthof","year":"2014","unstructured":"Olthof ED, Versleijen MW, Huisman-de Waal G, Feuth T, Kievit W, Wanten GJ. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions. PLoS ONE. 2014;9(11):e111216.","journal-title":"PLoS ONE"},{"issue":"4","key":"3413_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5301\/jva.5000168","volume":"14","author":"AH Al-Amin","year":"2013","unstructured":"Al-Amin AH, Sarveswaran J, Wood JM, Burke DA, Donnellan CF. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition. J Vasc Access. 2013;14(4):379\u201382.","journal-title":"J Vasc Access"},{"issue":"7","key":"3413_CR42","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1128\/AAC.02421-14","volume":"58","author":"N Fontser\u00e9","year":"2014","unstructured":"Fontser\u00e9 N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, et al. Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients. Antimicrob Agents Chemother. 2014;58(7):4180\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3413_CR43","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1177\/1129729820942040","volume":"22","author":"M Jimenez Hernandez","year":"2021","unstructured":"Jimenez Hernandez M, Soriano A, Filella X, Calvo M, Coll E, Rebled JM, et al. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation. J Vasc Access. 2021;22(3):370\u20139.","journal-title":"J Vasc Access"},{"key":"3413_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107627","volume":"215","author":"F Stanke-Labesque","year":"2020","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, Guilhaumou R. Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment. Pharmacol Ther. 2020;215:107627.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"3413_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0148607114525804","volume":"39","author":"S Klek","year":"2015","unstructured":"Klek S, Szczepanek K, Hermanowicz A, Galas A. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial. J Parenter Enter Nutr. 2015;39(3):331\u20135.","journal-title":"J Parenter Enter Nutr"},{"issue":"2","key":"3413_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5301\/jva.5000312","volume":"16","author":"K Chapla","year":"2015","unstructured":"Chapla K, Oza-Gajera BP, Yevzlin AS, Shin J-I, Astor BC, Chan MR. Hemodialysis catheter locking solutions and the prevention of catheter dysfunction: a meta-analysis. J Vasc Access. 2015;16(2):107\u201312.","journal-title":"J Vasc Access"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03413-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03413-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03413-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:04:28Z","timestamp":1763471068000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03413-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3413"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03413-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee of the Iran University of Medical Sciences approved the research protocol in accordance with the ethical code IR.IUMS.REC.1402.598. The trial was registered at the Iranian Registry of Clinical Trials as IRCT20201107049296N4. In accordance with the Helsinki Convention, and after obtaining informed consent from the patients (informed consent was obtained from parents for patients under the age of consent and from the patients themselves for those over the age of consent), the patients were included in the study. Children and their parents were given written information and were told they could leave the study protocol whenever they wanted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The lead author Aziz Eghbali, Kazem ghaffari affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1137"}}